Health & bio
Lilly buys Centessa, plants neuroscience flag with OX2R agonist
Eli Lilly scoops Centessa for $6.3B upfront plus $1.5B CVR, gaining cleminorexton OX2R agonist for narcolepsy and idiopathic hypersomnia.
Primary sources · 1
Eli Lilly scoops Centessa for $6.3B upfront plus $1.5B CVR, gaining cleminorexton OX2R agonist for narcolepsy and idiopathic hypersomnia.
7 must-reads · 17 fields · tracked storylines delivered to your inbox daily. Pick only the fields you want; unsubscribe anytime.